Causeway Capital Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$80.4M Buy
1,677,615
+503,402
+43% +$21.6M 0.87% 21
2026
Q1
$43.2M Buy
1,174,213
+180,363
+18% +$8.55M 0.53% 46
2025
Q4
$50.6M Buy
993,850
+297,871
+43% +$15.2M 0.7% 38
2025
Q3
$38.6M Buy
695,979
+342,095
+97% +$20M 0.51% 49
2025
Q2
$24.4M Buy
+353,884
New +$24.1M 0.39% 56

Other funds holding NVO

Causeway Capital Management's NVO Position: Q2 2026 in Review

Causeway Capital Management increased its Novo Nordisk (NVO) stake by 43% in Q2 2026, buying an estimated $21.6M and bringing the position to 1,677,615 shares worth $80.4M. The position accounts for 0.87% of the portfolio, ranked #21.

Causeway Capital Management first reported a position in NVO in Q2 2025 and has held it in 5 quarters since. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Causeway Capital Management held 1,677,615 shares of Novo Nordisk worth $80.4M as of Q2 2026.
  • Causeway Capital Management bought 503,402 Novo Nordisk shares in Q2 2026, an estimated $21.6M.
  • Novo Nordisk made up 0.87% of Causeway Capital Management's portfolio in Q2 2026, its #21 holding.
  • Causeway Capital Management first reported a position in Novo Nordisk in Q2 2025 and has held it in 5 quarters since.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Causeway Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.